3Celli BR,MacNee W.Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper(J).Eur Respir J,2004;23(6):932-46.
3Wilson SJ, Wallin A, Sandstrom T, et al. Effect of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med,2001,164 (6) : 1047 - 1052.
4Sandek K, Bratel T, Lagerstrand L. Effects on diffusing capacity and ventilation-perfusion relationships of budesonide inhalations for 2 months in chronic obstructive pulmonary disease (COPD). Respir Meal,2001,95(8) :676 -684.
5Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med,2001,164(8) :1414- 1418.
6Oostenbrink JB,AL MJ, Vincken W, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J,2004,23(2) :241 -249.
7Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med,2003,167(6) :813 -818.
8Culpitt SV, Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2002, 165 (10) : 1371 - 1376.
9Soprano B, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/ without longacting β-agonists reduce the risk of rehospitallization and death in COPD patients. Am J Respir Crit Care Med, 2003,2 (1) :67 -74.
10Calverley P, aulwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet,2003,361 (9356) :449 - 456.
